Milestone Scientific (MLSS) 3.11 $MLSS Milestone

New Post Public Reply Private Reply Replies (0) Message Board

Jun 8, 2016 at 3:03 PM

Milestone Scientific (MLSS) 3.11 $MLSS

Milestone Scientific Announces Completion of Clinical Trials for Its Epidural Instrument
Marketwired - Mon Jun 06, 8:10AM CDT
Reports Statistical Analysis Underway; Announces Plans to Submit Data to FDA
MLSS: 3.11 (+0.14)

Milestone Scientific Announces Completion of Enrollment in Clinical Trials for Its Epidural Instrument
Marketwire Canada - Thu May 26, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 26, 2016) - Milestone Scientific Inc (NYSE MKT: MLSS) today announced it has completed enrollment in its COMPASS Study (CompuFlo® Assessment Study), a randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the epidural space verification with the CompuFlo® Epidural Computer Controlled System. The clinical trial for the epidural instrument reached its target of enrolling 400 patients and consists of two separate arms: (i) pain management; and (ii) labor and delivery. Both arms will be compared against the current medical standards of care. The goal of the pivotal IDE clinical trial is to demonstrate the accuracy of the CompuFlo technology in identifying and confirming the epidural space location.
MLSS: 3.11 (+0.14)

Milestone Scientific Announces Board Approval of Follow-on Financing
Marketwired - Mon May 23, 6:30AM CDT
LIVINGSTON, NJ--(Marketwired - May 23, 2016) - Milestone Scientific Inc (NYSE: MLSS) today announced the Company's Board of Directors has approved a follow-on financing, expected to close in the coming weeks, with a group of investors that participated in the Company's May 2014 financing. The group will invest an additional $1.7 to $2.0 million in a private placement of unregistered common stock at $2.00 per share. There were no fees associated with the financing and the investors will not receive warrants or other special preferences related to the financing.
MLSS: 3.11 (+0.14)

Milestone Scientific Reports 29% Increase in Revenue for the First Quarter of 2016
Marketwired - Tue May 17, 6:45AM CDT
LIVINGSTON, NJ--(Marketwired - May 17, 2016) - Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the first quarter ending March 31, 2016.
MLSS: 3.11 (+0.14)

Milestone Scientific Schedules First Quarter 2016 Earnings Conference Call
Marketwire Canada - Mon May 16, 7:02AM CDT
LIVINGSTON, NJ--(Marketwired - May 16, 2016) - Milestone Scientific Inc. (NYSE: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:30 AM Eastern Time on Tuesday, May 17, 2016 to discuss the Company's financial results for the first quarter ended March 31, 2016, as well as the Company's corporate progress and other developments.
MLSS: 3.11 (+0.14)

Milestone Scientific Increases Ownership Stake in Epidural & Intra-Articular Subsidiary to 87%
Marketwired - Wed Apr 20, 9:00AM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that investors in the Company's Epidural & Intra-Articular Subsidiary, Milestone Medical Inc. ("Milestone Medical"

, representing 37% of the outstanding shares of shares of Milestone Medical, have agreed to convert their ownership into shares of Milestone Scientific, Inc. As a result, Milestone Scientific issued 4,090,000 new restricted shares to Milestone Medical investors, and now owns 87% of Milestone Medical.
MLSS: 3.11 (+0.14)

Milestone Scientific Reports Fourth Quarter and Year End 2015 Financial Results; Provides Update on Status of Clinical Trials for Epidural Instrument
Marketwired - Thu Apr 07, 1:03PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced financial results for the fourth quarter and year ended December 31, 2015, and provided a business update including an update on its minority owned subsidiary which holds the exclusive rights to the epidural and intra-articular (IA) instruments ("Epidural & IA Subsidiary"

.
MLSS: 3.11 (+0.14)

Milestone Scientific Schedules Fourth Quarter 2015 Earnings Conference Call
Marketwired - Thu Apr 07, 9:47AM CDT
Milestone Scientific Inc . (NYSE MKT: MLSS) , a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will host a conference call at 8:00 AM Eastern Time on Monday, April 11, 2016 to discuss the Company's financial results for the fourth quarter and year ended December 31, 2015, as well as the Company's corporate progress and other developments.
MLSS: 3.11 (+0.14)

Milestone Scientific Announces Plan to Reschedule 2015 Earnings Conference Call
Marketwired - Wed Mar 30, 3:05PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that it will reschedule the 2015 year-end conference call originally planned for March 31, 2016.
MLSS: 3.11 (+0.14)

Milestone Scientific to Ring Closing Bell at New York Stock Exchange
Marketwired - Mon Mar 28, 2:51PM CDT
Milestone Scientific Inc. (NYSE MKT: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that Leonard Osser, CEO, Gian Domenico Trombetta, President of Wand Dental, and other members of the senior management team will ring the NYSE Closing BellÂ® today, March 28th, in celebration of the Company's recent listing on the NYSE MKT.
MLSS: 3.11 (+0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zinzino's 2027 Nomination Committee Prepares for AGM

Unveiling Zinzino's New Nomination Committee Ah, Gothenburg—the city known for its beautiful canals and now, yet another lineup change for Zinzino AB's Nomination Committee. This is part and parcel of the games companies play before their Annual General Meetings (AGM) and generally an indicator of either stasis or shifts ahead. The names on the roster for Zinzino’s...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...

First-Time Clermont Homebuyers Face Unexpected Hurdles

Welcome to the Wild Ride of Buying a Home! When folks step into the homebuying ring, especially in places like Clermont, Florida, they often don't realize how chaotic things can get. It's like being thrown into a boxing match without gloves. Brandie Mathison-Klein from the Mathison-Klein Group shines a light on this in a HelloNation piece, spilling the beans on what...

APEC Summit 2026: Shenzhen in the Spotlight

An International Stage for Shenzhen Alright, folks, here's the deal. We’ve got the 2026 APEC Summit rolling into Shenzhen, perched right there in Guangdong Province, and the world’s eyes are glued to it. Happens November 18–19, and you better believe it’s a magnet for all things global. The China Media Group’s Chinese Global Program Center isn’t missing a...

Stent or Meds? Long-Term Study Questions Benefits

The Long Game in Cardiology There's this long-standing debate in cardiology about whether sticking a metal stent in an artery actually prevents heart attacks or just looks impressive. Well, after chewing on 25 years of data from the COURAGE trial, CU Anschutz researchers led by Dr. Neel Butala have thrown a curveball — these stents might not be as life-saving as many...

Etavopivat Aims to Tackle Sickle Cell Crisis Head-On

Diving headfirst into the world of sickle cell disease, Novo Nordisk has just thrown its hat in the ring with etavopivat. Now, anyone who's been following the biotech dance knows this ain't no small feat. This investigational therapy is poised to shake things up, offering a new lifeline for those wrestling with this debilitating condition. And leaping from the Phase 3...

GAC's AION i60 Rolls Out Overseas with Bold Ambitions

New Horizons for GAC's AION i60 Picture this: November 7, just another balmy day in Jakarta, yet something big was brewing in the streets—a fresh contender stepped into the global NEV arena. Introducing the AION i60, the latest model from China's GAC Group, now making waves overseas. With more than 100,000 sales back home, this is GAC's bold move to spread its wings on...

New Dog Leash Innovation Eases Dog Owner Struggles

A real game-changer in dog-walking gear could be sitting right under our noses, and it's coming straight from an inventor in Grand Junction, Colorado. Picture this: you're navigating a tight store aisle, juggling a toddler, a shopping cart, and a squirming dog. This ain't exactly the time for your leash to make life harder. Enter the SHOP & WALK DOG LEASH. This doohickey...

iQIYI's Global Reach Grows with Awards Recognition

Tony Leung Steals the Spotlight In the theater of Asian cinema, Tony Ka-fai Leung delivers a top-tier performance, earning him the Best Actor award at the Golden Rooster Awards for iQIYI's film "The Shadow's Edge." Now, let's not kid ourselves, snagging one of these prestigious awards is no walk in the park. It's fair to say both this recognition and his first-time win at...

NuScale Faces Class Action: Investor Notice Issued

Unveiling the Legal Clouds Over NuScale Power Rough seas are ahead for NuScale Power Corporation, as shareholder rights law firm Robbins LLP laid down the gauntlet. It's a tale as old as the markets—companies puffing out their chest and then getting caught with their hand in the cookie jar. Investors who took a leap of faith on NuScale's promises between February 27,...